Latest News - Eli Lilly

Top Corporates Hub

Eli Lilly

LLY | NYSE | United States
14
Rank
$706.44B
-$ 102.21B
-12.64%
Market Cap
$45.04B
+$ 4.18B
+10.23%
Revenue
$12.68B
+$ 4.31B
+51.49%
Earnings
47K
+4K
+9.3%
Employees
Sector Update: Healthcare Stocks Rise in Afternoon Trading

10.08.2026 17:40

Healthcare stocks were higher Monday afternoon, with the NYSE Healthcare Index up 0.9% and the State

Read More

Eli Lilly Stock's Next Climb Runs Through A Pill, Not Just An Injection

10.08.2026 16:01

The case for more upside rests on its obesity pill, and what changed is not the drug but who can now write it and who can now pay for it.

Read More

Is IMCR Worth Buying as Kimmtrak Growth Meets a Premium Valuation?

10.08.2026 15:41

Immunocore's Kimmtrak growth and late-stage catalysts strengthen its case, but a premium valuation and single-product risk raise the stakes.

Read More

This Biotech’s Drug Could Treat Hot Flashes. The Stock Is Up 36% on Good News.

10.08.2026 14:12

New data show a single dose of AbCellera’s menopause treatment, ABCL635, reduces how often patients with menopause experience hot flashes.

Read More

Lifespan Vision Ventures Leads Remedium Bio's Series A Financing

10.08.2026 14:00

Lifespan Vision Ventures today announced that it is leading Remedium Bio, Inc.'s ("Remedium") $10 million Series A financing and has completed the round's initial closing, with participation from Eli Lilly and Company ("Lilly") and HKX Capital. In connection with the financing, Harry Robb of Lifespan Vision Ventures has joined Remedium's Board of Directors.

Read More

Weight-Loss Drugs - How Are GLP-1s Redistributing Consumer Spending?

10.08.2026 13:35

The recent increasing adoption of GLP-1 drugs has fundamentally changed the landscape of weight loss and health habits.

Read More

Pfizer Rises Almost 7% Post Q2 Results: How to Play the Stock

10.08.2026 13:17

Pfizer's Q2 beat and raised 2026 revenue outlook signal progress, but declining COVID sales and patent losses challenge its growth path.

Read More

Eli Lilly (NYSE:LLY) Pairs High Growth Momentum with a Defined Breakout Setup

10.08.2026 12:11

Eli Lilly (LLY) passes high-growth momentum screen with strong earnings, sales acceleration, and technical setup. See why LLY scores well.

Read More

3 Beaten-Down Healthcare Stocks to Buy in August

10.08.2026 12:00

Healthcare just posted the best three-month run of any S&P 500 sector, yet two of the three biggest pharma names by market cap are still trailing the broader market. That gap between performance and fundamentals is creating a window that income and growth investors rarely see at the mega-cap level.

Read More

Eli Lilly (LLY) Posts Blowout Growth And Raises Its Outlook

09.08.2026 08:51

Eli Lilly (NYSE:LLY) delivered a quarter that forced Wall Street to catch up to its own numbers. On August 5, the company reported second-quarter revenue of $23.0 billion, up 48% from a year earlier, and used the momentum to raise its full-year sales and profit targets. Shares moved higher the same day as investors focused […]

Read More

BofA points to the Eli Lilly market that could outsize the U.S.

08.08.2026 18:33

Eli Lilly (LLY) posted a second-quarter result strong enough to shift the debate around its stock. For months, the debate centered on one worry: a slow start for its new obesity pill. That worry did not disappear in the second quarter, but it stopped driving the conversation. Bank of America came ...

Read More

Eli Lilly and Company Q2 Earnings Call Highlights

08.08.2026 16:04

Eli Lilly and Company (NYSE:LLY) reported 48% revenue growth in the second quarter of 2026, driven primarily by continued demand for its cardiometabolic medicines MOUNJARO and ZEPBOUND, while raising its full-year revenue and earnings guidance. Chair and CEO Dave Ricks said the company delivered gr

Read More

Novo Nordisk: Dismal Q2 Earnings, Operational Frailties Warrant Rating Downgrade

07.08.2026 10:55

Novo Nordisk A/S gets a Sell rating as profits slide, guidance weakens, and competition rises vs Eli Lilly. Click for this NVO stock update and a look at earnings.

Read More

Why Big Pharma is chasing the industry’s most-powerful supercomputer

07.08.2026 09:20

BMS is the latest major drugmaker to tap Nvidia for more computing power, betting that larger models and AI agents can speed drug discovery.

Read More

Truist Securities Maintains Buy on Eli Lilly, Raises Price Target to $1376

07.08.2026 09:16

Truist Securities analyst Robyn Karnauskas maintains Eli Lilly (NYSE:LLY) with a Buy and raises the price target from $1370 to $1376.

Read More

CVS Health (CVS) Is Down 8.6% After Raising 2026 Guidance And Expanding GLP-1 Tie-Up With Lilly – Has The Bull Case Changed?

07.08.2026 09:11

In early August 2026, CVS Health reported second-quarter results showing higher sales of US$35,117 million and revenue of US$106.10 billion, alongside net income of US$2,979 million and materially higher earnings per share versus a year earlier. On the same day, CVS Health also raised its 2026 earnings guidance and expanded its GLP-1 weight management offering through a new collaboration with Eli Lilly, underscoring how integrated pharmacy, insurance and care-delivery assets can be combined...

Read More

Jim Cramer Calls This Industrial Stock ‘Sensational’ And Ameriprise Financial ‘Fantastic’

07.08.2026 08:14

Jim Cramer praises Lockheed Martin and Ameriprise Financial, advises against Cipher Digital. Eli Lilly to acquire AtaiBeckley for $3.8B.

Read More

How To Earn $500 A Month From Eli Lilly Stock Ahead Of Q2 Earnings

06.08.2026 03:31

Eli Lilly and Company will release its second-quarter earnings report before the opening bell on Wednesday, Aug. 5. Analysts expect the company to report quarterly earnings of $6.58 per share, up from $6.31 per share in the year-ago period. The...

Read More

Eli Lilly Q2: Strong Results Further Strengthen The Investment Thesis

06.08.2026 02:09

Eli Lilly raised 2026 revenue guidance to $85–87B, driven by volume gains despite price declines, and reinforced margin expansion. Read why LLY stock is a Buy.

Read More

Novo Nordisk Is Exiting a ‘Rough Patch,’ CFO Says. Earnings Prove It.

05.08.2026 17:49

The Danish drugmaker continues to rely on the success of semaglutide, branded as Wegovy for weight loss and Ozempic for diabetes.

Read More